HUTCHMED (China) Limited announced that the New Drug Application (?NDA?) for tazemetostat for the treatment of adult patients with relapsed or refractory (?R/R?) follicular lymphoma (?FL?) has been accepted for review and granted Priority Review by the China National Medical Products Administration (?NMPA?). Tazemetostat is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme Inc. (?Epizyme?), an Ipsen company. Tazemetostat is approved by the U.S. Food and Drug Administration (?FDA?) for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma (?ES?) under the FDA accelerated approval program.

It is also approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for certain patients with R/R FL. HUTCHMED entered into a strategic collaboration to research, develop, manufacture and commercialize tazemetostat in China, Hong Kong, Macau and Taiwan. This China NDA is supported by results from a multicenter, open-label, Phase II bridging study in China, and clinical studies conducted by Epizyme outside China.

Tazemetostat was approved for use in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (Hainan Pilot Zone) in May 2022, under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with ES and FL consistent with the label as approved by the FDA. Tazemetostat was approved in the Macau Special Administrative Region (?SAR?) in March 2023 and in the Hong Kong SAR in May 2024.